Core Laboratories (CLB) director receives 7,895 restricted shares and holds 54,397

Rhea-AI Filing Summary

Core Laboratories director Martha Z. Carnes reported equity compensation activity involving restricted shares and common stock. She received a grant of 7,895 Restricted Shares on April 1, 2026, which will vest after a one-year vesting period ending April 1, 2027, subject to the terms of issuance.

On the same date, 8,069 previously granted Restricted Shares completed their one-year vesting period ending April 1, 2026 and were converted into 8,069 shares of Common Stock at no cash exercise price. Following these transactions, she directly holds 54,397 shares of Core Laboratories common stock.

Insider Trade Summary

8,069 shares exercised/converted

Mixed 3 txns

Insider Carnes Martha Z.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Shares	7,895	$0.00	--
Exercise	Restricted Shares	8,069	$0.00	--
Exercise	Common Stock	8,069	$0.00	--

Holdings After Transaction: Restricted Shares — 7,895 shares (Direct); Common Stock — 54,397 shares (Direct)

Footnotes (1)

1. The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board. The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026.

Key Figures

Restricted Share Grant: 7,895 Restricted Shares Vested Restricted Shares: 8,069 Restricted Shares Common Stock Acquired: 8,069 shares +2 more

5 metrics

Restricted Share Grant 7,895 Restricted Shares Granted April 1, 2026; one-year vesting period to April 1, 2027

Vested Restricted Shares 8,069 Restricted Shares Vested after one-year vesting period ending April 1, 2026

Common Stock Acquired 8,069 shares Common Stock received from conversion of vested Restricted Shares at $0.00 per share

Post-transaction holdings 54,397 Common Shares Direct ownership after Form 4 transactions

Transaction price per share $0.00 per share Reported for Restricted Shares and Common Stock in these transactions

Key Terms

Restricted Shares, vesting period, deferral election, Treasury Regulation 1.409A-2, +1 more

5 terms

Restricted Shares financial

"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period"

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

vesting period financial

"The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027"

A vesting period is the set amount of time someone must wait before they fully own granted shares, stock options, or other equity tied to their work or an agreement; ownership increases gradually or in steps during that time. Investors care because vesting determines when insiders or employees can sell shares, which affects future supply of stock, company incentives and executive retention—think of it like unlocking ownership over installments rather than receiving it all at once.

deferral election financial

"Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2"

Treasury Regulation 1.409A-2 financial

"subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2"

separation of service financial

"the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carnes Martha Z.

(Last) (First) (Middle)

6316 WINDFERN ROAD

(Street)

HOUSTON TEXAS 77040

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Core Laboratories Inc. /DE/ [ CLB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		M		8,069	A	$0	54,397	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Shares	$0	04/01/2026		A		7,895		(1)	(1)	Common Stock	7,895	$0	7,895	D
Restricted Shares	$0	04/01/2026		M			8,069	(2)	(2)	Common Stock	8,069	$0	0	D

Explanation of Responses:

1. The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board.

2. The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026.

	/s/ Mark Tattoli, Attorney-in-Fact	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Core Laboratories (CLB) director Martha Carnes report?

Martha Z. Carnes reported equity compensation activity, not open-market trades. She received 7,895 Restricted Shares and saw 8,069 previously granted Restricted Shares vest into Common Stock, all at a transaction price of $0.00 per share as part of her director compensation.

How many Core Laboratories (CLB) restricted shares were granted to Martha Carnes?

She was granted 7,895 Restricted Shares on April 1, 2026. These shares are scheduled to vest after a one-year vesting period ending April 1, 2027, subject to the terms of issuance, and may be subject to a deferral election under Treasury Regulation 1.409A-2.

When do Martha Carnes’ new Core Laboratories restricted shares vest?

The 7,895 Restricted Shares granted to Martha Carnes vest at the end of a one-year vesting period on April 1, 2027. Under the deferral election, vested shares will be distributed as common stock after her separation of service from the Board, according to the terms described.

What happened to Martha Carnes’ previously granted Core Laboratories restricted shares?

A prior award of 8,069 Restricted Shares vested at the end of a one-year vesting period on April 1, 2026. Those Restricted Shares were then exercised or converted into 8,069 shares of Common Stock, with a reported transaction price and exercise price of $0.00 per share.

How many Core Laboratories common shares does Martha Carnes own after these transactions?

After these transactions, Martha Z. Carnes directly owns 54,397 shares of Core Laboratories Common Stock. This figure reflects her holdings following the conversion of 8,069 vested Restricted Shares into Common Stock, as reported in the insider filing data provided.

Were there any open-market buys or sells by Martha Carnes in this Core Laboratories Form 4?

No open-market purchases or sales were reported. The Form 4 shows only equity compensation-related activity: a grant of 7,895 Restricted Shares and the vesting and conversion of 8,069 Restricted Shares into Common Stock, all at a transaction price of $0.00 per share.